Abstract
Allergen immunotherapy (AIT) is the only therapeutical method in treatment of allergic diseases which causally intervenes development of specific immunological hypersensitivity and is able to suppress allergic sensitisation of an atopic patient. According to present knowledge, helper T-lymphocytes are deemed the target of the modulation intervention of therapy.
Shift from Th2/Th0 clone (prevailing in atopic patients) in favour of Th0/Th1 clone is supposed. This shift is verified by changes in interleukins production and in following stages of immune response.
The use of allergen immunotherapy in polysensitized asthmatics with coincidence of allergic diseases seems to be limited.